No clinically significant pharmacokinetic interaction appears to occur between
aciclovir and
mycophenolate. However, the manufacturers say that in
renal impair- ment there may be competition for tubular secretion and increased concentrations of both drugs may occur. This is also possible with valaciclovir. A case report describes
neutropenia in a patient taking valaciclovir with
mycophenolate.
No action is needed, but increased monitoring may be prudent in patients with reduced
renal function.
Neutropenia is a rare adverse effect of valaciclovir alone. Nevertheless, bear the possibility of an interaction in mind should
neutropenia occur if
mycophenolate is also given.